{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03301038",
            "orgStudyIdInfo": {
                "id": "16-013429"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01DK112955",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01DK112955"
                }
            ],
            "organization": {
                "fullName": "Children's Hospital of Philadelphia",
                "class": "OTHER"
            },
            "briefTitle": "Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria",
            "officialTitle": "Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Inactivating Mutations in the CYP24A1 Gene",
            "acronym": "RICHH",
            "therapeuticArea": [
                "Rare Diseases",
                "Pediatrics",
                "Other"
            ],
            "study": "rifampin-in-related-hypercalcemia-and-hypercalciuria"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-07-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2017-09-01",
            "studyFirstSubmitQcDate": "2017-09-29",
            "studyFirstPostDateStruct": {
                "date": "2017-10-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-03",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Children's Hospital of Philadelphia",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.",
            "detailedDescription": "Idiopathic infantile hypercalcemia (IIH; omim 143880) is a genetic disorder of mineral metabolism characterized by severe hypercalcemia and/or hypercalciuria, suppressed serum levels of parathyroid hormone (PTH) and elevated levels of the active vitamin D metabolite, 1,25(OH)2D. Biallelic inactivating mutations of CYP24A1, the gene encoding the 24-hydroxylase enzyme that represents the principal pathway for inactivation of vitamin D metabolites, cause the most common and severe form of IIH.\n\nInvestigators have preliminary data supporting a novel therapeutic approach to repurpose rifampin as an agent to induce over-expression of CYP3A4 and CYP3A5, enzymes that are expressed in the liver and intestine. When these enzymes are induced, the increased enzyme activity provides an alternative catabolic pathway for inactivation of vitamin D metabolites. The purpose of this study is to obtain support for an open label, escalating dose study to assess the effect, safety, and tolerability of once daily oral rifampin in participants with IIH due to inactivating mutations in CYP24A1.\n\nIn this study, Investigators will recruit 30 patients with at least one inactivating mutation of CYP24A1. Participants will be observed for 8-weeks before a 16-week treatment phase of rifampin and 8 further weeks of observation. In addition to following the effect of treatment on calcium homeostasis, Investigators will also study the pharmacokinetics of rifampin in this condition and the effect on intestinal calcium absorption."
        },
        "conditionsModule": {
            "conditions": [
                "Idiopathic Infantile Hypercalcaemia - Severe Form",
                "Genetic Disease",
                "Hypercalcemia, Idiopathic, of Infancy",
                "Hypercalciuric Hypercalcemia",
                "Idiopathic Infantile Hypercalcemia - Mild Form",
                "Hypercalciuria"
            ],
            "keywords": [
                "hypercalcemia",
                "nephrocalcinosis",
                "CYP24A1",
                "hypercalciuria"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "All Subjects",
                    "type": "EXPERIMENTAL",
                    "description": "SingleArm: Escalating doses of rifampin (5 and 10 mg/kg/day) (SingleArm)",
                    "interventionNames": [
                        "Drug: Rifampin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Rifampin",
                    "description": "Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.",
                    "armGroupLabels": [
                        "All Subjects"
                    ],
                    "otherNames": [
                        "Rifadin",
                        "Rifampicin"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Serum albumin-adjusted calcium",
                    "description": "Measured at baseline and every 4 weeks",
                    "timeFrame": "up to 32 weeks"
                },
                {
                    "measure": "Serum parathyroid hormone",
                    "description": "Measured at baseline and every 4 weeks",
                    "timeFrame": "up to 32 weeks"
                },
                {
                    "measure": "Urinary calcium excretion",
                    "description": "Measured at baseline and every 4 weeks",
                    "timeFrame": "up to 32 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Intestinal calcium absorption",
                    "description": "Measured using stable calcium isotopes five times during the study",
                    "timeFrame": "baseline, 8, 16, 24 and 32 weeks post-dose"
                },
                {
                    "measure": "Nephrocalcinosis",
                    "description": "Renal ultrasound performed before and after treatment",
                    "timeFrame": "Baseline and week 32"
                },
                {
                    "measure": "Rifampin pharmacokinetics",
                    "description": "Measured three times during the study",
                    "timeFrame": "8, 16 and 24 weeks post-dose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Males or females age 6 months to 65 years.\n* at least one mutations of CYP24A1\n* Serum and/or urinary calcium above the normal reference range for age\n* Serum PTH concentration \\<20 pg/ml\n* Elevated or normal serum concentration of 1,25-dihydroxyvitamin D3.\n\nExclusion Criteria:\n\n* Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.\n* Allergy to rifampin or related medications\n* Current therapies with medications that have significant drug-drug interactions with rifampin, defined as a medication considered to interact with CYP3A4 or CYP3A5 and either induce or inhibit expression or function of these P450 enzymes. By \"drug-drug\" interactions we are looking for medications that will affect metabolism or action of rifampin as exclusionary, not medications that will be affected by rifampin.\n* Pregnancy or breastfeeding\n* Laboratory abnormalities that indicate clinically significant hepatic, or renal disease:\n\nAspartate Aminotransferase (AST/SGOT) \\> 2.0 times the upper limit of normal Alanine aminotransferase (ALT/SGPT) \\> 2.0 times the upper limit of normal Total bilirubin \\> 2.0 times the upper limit of normal Creatinine \\> 2.0 times the upper limit of normal",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "6 Months",
            "maximumAge": "65 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Michael A Levine, MD",
                    "role": "CONTACT",
                    "phone": "267-426-3907",
                    "email": "levinem@chop.edu"
                },
                {
                    "name": "Vashisht Arshanapally",
                    "role": "CONTACT",
                    "phone": "267-426-7482",
                    "email": "arshanapav@chop.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Michael A Levine, MD",
                    "affiliation": "Children'sHospital of Philadelphia",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Children's Hospital of Philadelphia",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michael A Levine, MD",
                            "role": "CONTACT",
                            "phone": "267-426-3907",
                            "email": "levinem@chop.edu"
                        },
                        {
                            "name": "Sara Pinney, MD",
                            "role": "CONTACT",
                            "phone": "215-590-3174",
                            "email": "PINNEYS@chop.edu"
                        },
                        {
                            "name": "Sara Pinney, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Michael A Levine, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "28324001",
                    "type": "BACKGROUND",
                    "citation": "Hawkes CP, Li D, Hakonarson H, Meyers KE, Thummel KE, Levine MA. CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations. J Clin Endocrinol Metab. 2017 May 1;102(5):1440-1446. doi: 10.1210/jc.2016-4048."
                },
                {
                    "pmid": "22112808",
                    "type": "BACKGROUND",
                    "citation": "Dauber A, Nguyen TT, Sochett E, Cole DE, Horst R, Abrams SA, Carpenter TO, Hirschhorn JN. Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J Clin Endocrinol Metab. 2012 Feb;97(2):E268-74. doi: 10.1210/jc.2011-1972. Epub 2011 Nov 23."
                },
                {
                    "pmid": "21675912",
                    "type": "BACKGROUND",
                    "citation": "Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, Misselwitz J, Klaus G, Kuwertz-Broking E, Fehrenbach H, Wingen AM, Guran T, Hoenderop JG, Bindels RJ, Prosser DE, Jones G, Konrad M. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011 Aug 4;365(5):410-21. doi: 10.1056/NEJMoa1103864. Epub 2011 Jun 15."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000007232",
                    "term": "Infant, Newborn, Diseases"
                },
                {
                    "id": "D000008661",
                    "term": "Metabolism, Inborn Errors"
                },
                {
                    "id": "D000006934",
                    "term": "Hypercalcemia"
                },
                {
                    "id": "D000053565",
                    "term": "Hypercalciuria"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002128",
                    "term": "Calcium Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000014883",
                    "term": "Water-Electrolyte Imbalance"
                },
                {
                    "id": "D000020924",
                    "term": "Urological Manifestations"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9985",
                    "name": "Hypercalcemia",
                    "asFound": "Hypercalcemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12342",
                    "name": "Nephrocalcinosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M27341",
                    "name": "Hypercalciuria",
                    "asFound": "Hypercalciuria",
                    "relevance": "HIGH"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "asFound": "Genetic Diseases",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10276",
                    "name": "Infant, Newborn, Diseases",
                    "asFound": "Idiopathic Infantile Hypercalcemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11641",
                    "name": "Metabolism, Inborn Errors",
                    "asFound": "Idiopathic Infantile Hypercalcemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5391",
                    "name": "Calcium Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17624",
                    "name": "Water-Electrolyte Imbalance",
                    "relevance": "LOW"
                },
                {
                    "id": "M22659",
                    "name": "Urological Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "T4071",
                    "name": "Nephrocalcinosis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012293",
                    "term": "Rifampin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000904",
                    "term": "Antibiotics, Antitubercular"
                },
                {
                    "id": "D000000995",
                    "term": "Antitubercular Agents"
                },
                {
                    "id": "D000000900",
                    "term": "Anti-Bacterial Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000007917",
                    "term": "Leprostatic Agents"
                },
                {
                    "id": "D000019384",
                    "term": "Nucleic Acid Synthesis Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000065695",
                    "term": "Cytochrome P-450 CYP2B6 Inducers"
                },
                {
                    "id": "D000065693",
                    "term": "Cytochrome P-450 Enzyme Inducers"
                },
                {
                    "id": "D000065696",
                    "term": "Cytochrome P-450 CYP2C8 Inducers"
                },
                {
                    "id": "D000065697",
                    "term": "Cytochrome P-450 CYP2C19 Inducers"
                },
                {
                    "id": "D000065698",
                    "term": "Cytochrome P-450 CYP2C9 Inducers"
                },
                {
                    "id": "D000065701",
                    "term": "Cytochrome P-450 CYP3A Inducers"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5381",
                    "name": "Calcium",
                    "relevance": "LOW"
                },
                {
                    "id": "M5398",
                    "name": "Calcium, Dietary",
                    "relevance": "LOW"
                },
                {
                    "id": "M15118",
                    "name": "Rifampin",
                    "asFound": "Color",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M4311",
                    "name": "Antitubercular Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "BDCA",
                    "name": "Bone Density Conservation Agents"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}